



Targeted Market(s): Academic and pharmaceutical genomic research laboratories worldwide.

Competitive Advantage: ExCyto[®] competent cells dramatically reduce DNA amplification and sequencing costs.

*Technology funded by the NHGRI and being commercialized under the NIH-CAP

Board of Directors: Ralph Kauten, (Chairman), CEO of Quintessence Biosciences, a biotechnology company developing new cancer therapeutics.

Chris Fortune, President and CEO of SARIS Cycling Group, a developer and manufacturer of cycling equipment.

Tim Konicek, Director of Venture Investments for CleanTech Parners, a private, non-profit organization that invests in emerging, energy-saving technologies.

Product Pipeline

